ClinicalTrials.gg
CompletedNCT02195479Updated Aug 22, 2025Results posted

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

A Phase 3 interventional study of Velcade and Melphalan in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 160 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
706
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
7th of 132
706 · median 50
Started
2014
with 3 others
Phase 3
24 of 132
4 open now
Registered
6th of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 7th largest by enrollment, is one of 4 that started in 2014, is one of 24 in phase 3, and was the 6th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously untreated multiple myeloma who are ineligible for high dose chemotherapy and autologous stem cell transplant (ASCT).

Read the detailed description

The study consists of 3 phases: Screening Phase (within 21 days prior to randomization), Treatment Phase (Cycle 1 Day 1 to discontinuation of all study treatment), and Follow-up Phase (from discontinuation of all study treatment up to death, lost to follow up, withdrawal of consent, or the study ends, whichever occurs first). Treatment phase will include 2 treatments (Treatment A: participants will receive Velcade MelphalanPrednisone (VMP) alone and Treatment B: participants will receive daratumumab in combination with VMP).Two interim analyses are planned. The first will be to evaluate safety after a total of approximately 100 participants have been treated for at least 2 cycles or discontinued the study treatment. The second will be to evaluate cumulative interim safety and efficacy data, and will be performed when approximately 216 PFS events have been accumulated. The final OS analysis will occur when approximately 382 deaths have occurred. Efficacy will be primarily measured by comparison of PFS between the two treatment arms. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Bortezomib
  • Velcade
  • Melphalan
  • Prednisone
  • Daratumumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have documented multiple myeloma satisfying the calcium elevation, renal insufficiency, anemia, and bone abnormalities (CRAB) diagnostic criteria, monoclonal plasma cells in the bone marrow greater than or equal to 10 percent (%) or presence of a proven plasmacytoma, and measurable secretory disease, as assessed by the central laboratory, and defined in protocol
  • Participants who are newly diagnosed and not considered candidate for high-dose chemotherapy with stem cell transplantation (SCT) due to: being age >=65 years, or in participants \<65 years: presence of important comorbid conditions likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation
  • Participant must have an (ECOG) performance status score of 0, 1, or 2
  • Meet the clinical laboratory criteria as specified in the protocol
  • A woman of must have a negative serum pregnancy test at screening within 14 days prior to randomization
  • Women of childbearing potential must commit to either abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable simultaneously. This includes one highly effective form of contraception (tubal ligation, intrauterine device, hormonal [birth control pills, injections, hormonal patches, vaginal rings or implants] or partner's vasectomy) and one additional effective contraceptive method (male latex or synthetic condom, diaphragm, or cervical cap). Contraception must begin prior to dosing. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy or bilateral oophorectomy

Exclusion criteria

Exclusion Criteria:

  • Participant has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma
  • Participant has a diagnosis of Waldenstrom's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions
  • Participant has prior or current systemic therapy or SCT for multiple myeloma, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for 4 days) of before treatment
  • Participant has peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the national cancer institute (NCI CTCAE) Version 4
  • Participant has a history of (other than multiple myeloma) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years)
  • Participant has had radiation therapy within 14 days of randomization
  • Participant has had plasmapheresis within 28 days of randomization
  • Participant has known (COPD) (defined as a [FEV1] \<50% of predicted normal), known moderate or severe persistent asthma within the last 2 years or currently has uncontrolled asthma of any classification (controlled intermittent asthma or controlled mild persistent asthma is allowed)
  • Participants with known or suspected COPD must have a FEV1 test during screening
  • Participant is known to be seropositive for (HIV), known to have surface antigen positivity, or history of to have a history of
  • Participant has any concurrent medical or psychiatric condition or disease (example active systemic infection, uncontrolled diabetes, acute diffuse infiltrative pulmonary disease) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
706 participants (actual)

Study arms

  • Active comparator
    Treatment Arm A (VMP Alone)

    Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m\^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.

    Drug: Velcade · Drug: Melphalan · Drug: Prednisone

  • Experimental
    Treatment Arm B (D-VMP)

    Participants will receive velcade 1.3 mg/m\^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.

    Drug: Velcade · Drug: Melphalan · Drug: Prednisone · Drug: Daratumumab IV · Drug: Dexamethasone · Drug: Daratumumab SC

Interventions

  • Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.

  • Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.

  • Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.

  • Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .

  • Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.

  • Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS: duration from date of randomization to progressive disease (PD)/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 grams per deciliter \[g/dL\]); Urine M-component (absolute increase \>=200 milligrams \[mg\]/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow Plasma cells (PC) percentage (%) (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

    Time frame: From randomization (Day -3) up to 2.4 years

Secondary outcomes

  1. Overall Response Rate (ORR)

    The Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better, according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: greater than or equal to (\>=) 50 percentage (%) reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.

    Time frame: From randomization (Day -3) up to 2.4 years

  2. Percentage of Participants With Very Good Partial Response (VGPR) or Better

    VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.

    Time frame: From randomization (Day -3) up to 2.4 years

  3. Percentage of Participants With Complete Response (CR) or Better

    CR or better rate was defined as the percentage of participants with a CR or better (i.e. CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.

    Time frame: From randomization (Day -3) up to 2.4 years

  4. Percentage of Participants With Stringent Complete Response (sCR)

    sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells (PCs) in bone marrow.

    Time frame: From randomization (Day -3) up to 2.4 years

  5. Percentage of Participants With Negative Minimal Residual Disease (MRD)

    The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^-5 threshold. MRD was evaluated by using Deoxyribonucleic acid (DNA) sequencing of immunoglobulin genes. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR).

    Time frame: From randomization (Day -3) up to 8.3 years

  6. Overall Survival (OS)

    Overall Survival (OS) was measured from the date of randomization to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.

    Time frame: From randomization (Day -3) up to 8.3 years

  7. Progression Free Survival on Next Line of Therapy (PFS2)

    Progression-free survival after next-line therapy is defined as the time from randomization to progression on the next line of subsequent antimyeloma therapy or death due to any cause (prior to start of second line of antimyeloma therapy), whichever comes first. Disease progression on next line of treatment was based on investigator judgment.

    Time frame: From randomization (Day -3) up to 8.3 years

  8. Time to Disease Progression (TTP)

    TTP: Time from date of randomization to date of first documented evidence of PD or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cells (PC)% (absolute % \>=10%); Bone marrow PC %: absolute % \>10%; Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

    Time frame: From randomization (Day -3) up to 2.4 years

  9. Time to Response

    Time to response, defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours; If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.

    Time frame: From randomization (Day -3) up to 2.4 years

  10. Duration of Response (DOR)

    DOR: participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD: Increase of 25% from lowest response value in any one of following: Serum M-component (absolute increase\>=0.5 g/dL); Urine M-component (absolute increase\>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10mg/dL); Only participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC%(absolute%\>=10%); Bone marrow PC's %: absolute%\>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in the size of existing bone lesions or soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

    Time frame: From first documentation of response up to 2.4 years

  11. Time to Next Treatment (TNT)

    Time to next treatment is defined as the time from randomization to the start of the next-line treatment. Kaplan-Meier method was used for the analysis.

    Time frame: From randomization (Day -3) up to 8.3 years

  12. Percentage of Participants With Best M-protein Response

    Percentage of participants with Best M- protein response of 100% reduction and \>=90% to \< 100% reduction were assessed. Best M-protein response was defined as the maximal percent reduction or the lowest percent increase from baseline in serum M-protein for participants with measurable heavy chain at baseline or urine M-protein for participants without measurable heavy chain, but with measurable light chain disease at baseline. For participants without measurable heavy chain and light chain disease at baseline, best response in serum free light chain (FLC) was defined as the maximal percent reduction or the lowest percent increase from baseline in the difference between involved and uninvolved serum FLC level (dFLC).

    Time frame: Up to 2.4 years

  13. Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score

    The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.

    Time frame: Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48

  14. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Global Health Scale

    The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.

    Time frame: Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48

  15. Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS)

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Baseline (Day- 24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48

  16. Change From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score

    EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.

    Time frame: Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48

07

Results

Posted Dec 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Started356350
Treated354346
Completed00
Not completed356350
Withdrew: Lost to follow-up1815
Withdrew: Death217171
Withdrew: Physician decision10
Withdrew: Withdrawal by subject3030
Withdrew: Other34
Withdrew: Discontinued at clinical cutoff (due to end of data collection period)87130

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS: duration from date of randomization to progressive disease (PD)/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 grams per deciliter \[g/dL\]); Urine M-component (absolute increase \>=200 milligrams \[mg\]/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase \>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow Plasma cells (PC) percentage (%) (absolute % \>=10%); Bone marrow PC%: absolute% \>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Progression Free Survival (PFS)18.14 (16.53 to 19.91)NA (NA to NA)
SecondaryOverall Response Rate (ORR)

The Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better, according to the International Myeloma Working Group (IMWG) criteria, during the study or during follow up. IMWG criteria for PR: greater than or equal to (\>=) 50 percentage (%) reduction of serum M-protein and reduction in 24 hour urinary M-protein by \>=90% or to \<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%, in addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Overall Response Rate (ORR)73.990.9
SecondaryPercentage of Participants With Very Good Partial Response (VGPR) or Better

VGPR or better rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response\[sCR\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \>= 90% reduction in serum M-protein plus urine M-protein level less than (\<) 100 milligram (mg) per 24 hour; CR: negative immunofixation on the serum and urine, Disappearance of any soft tissue plasmacytomas and \< 5% plasms cells (PCs) in bone marrow; sCR: CR in addition to having a normal FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Very Good Partial Response (VGPR) or Better
Percentage of participantsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Percentage of Participants With Very Good Partial Response (VGPR) or Better49.771.1
SecondaryPercentage of Participants With Complete Response (CR) or Better

CR or better rate was defined as the percentage of participants with a CR or better (i.e. CR and sCR) as per IMWG criteria. CR: as negative immunofixation on the serum and urine and disappearance of soft tissue plasmacytomas and less than (\<) 5 percent plasma cells in bone marrow; sCR: CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (CR) or Better
Percentage of participantsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Percentage of Participants With Complete Response (CR) or Better24.442.6
SecondaryPercentage of Participants With Stringent Complete Response (sCR)

sCR as per IMWG criteria is CR plus normal free light chain (FLC) ratio and absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. CR: Negative immunofixation on the serum and urine; Disappearance of any soft tissue plasmacytomas; \<5% plasma cells (PCs) in bone marrow.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Stringent Complete Response (sCR)
Percentage of participantsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Percentage of Participants With Stringent Complete Response (sCR)7.018.0
SecondaryPercentage of Participants With Negative Minimal Residual Disease (MRD)

The Minimal Residual Disease negativity rate was defined as the percentage of participants who had negative MRD (detection of less than 1 malignant cell among 100,000 normal cells) assessment at any timepoint after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10\^-5 threshold. MRD was evaluated by using Deoxyribonucleic acid (DNA) sequencing of immunoglobulin genes. MRD was assessed in participants who achieved complete response or stringent complete response (CR/sCR).

Time frame:
From randomization (Day -3) up to 8.3 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Percentage of participantsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Percentage of Participants With Negative Minimal Residual Disease (MRD)7.0 (4.6 to 10.2)28.3 (23.6 to 33.3)
SecondaryOverall Survival (OS)

Overall Survival (OS) was measured from the date of randomization to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.

Time frame:
From randomization (Day -3) up to 8.3 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Overall Survival (OS)53.59 (46.32 to 60.91)82.96 (72.48 to NA)
SecondaryProgression Free Survival on Next Line of Therapy (PFS2)

Progression-free survival after next-line therapy is defined as the time from randomization to progression on the next line of subsequent antimyeloma therapy or death due to any cause (prior to start of second line of antimyeloma therapy), whichever comes first. Disease progression on next line of treatment was based on investigator judgment.

Time frame:
From randomization (Day -3) up to 8.3 years
Reported as:
Median · Months
Progression Free Survival on Next Line of Therapy (PFS2)
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Progression Free Survival on Next Line of Therapy (PFS2)42.41 (37.29 to 47.05)66.73 (58.58 to 80.07)
SecondaryTime to Disease Progression (TTP)

TTP: Time from date of randomization to date of first documented evidence of PD or death due to PD, whichever occurs first. PD per IMWG criteria- Increase of 25 % from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only in participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 milligram per deciliter \[mg/dL\]); Only in participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow plasma cells (PC)% (absolute % \>=10%); Bone marrow PC %: absolute % \>10%; Definite development of new bone lesions/soft tissue plasmacytomas or definite increase in size of existing bone lesions/soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Median · Months
Time to Disease Progression (TTP)
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Time to Disease Progression (TTP)19.35 (17.38 to 22.67)NA (NA to NA)
SecondaryTime to Response

Time to response, defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better. PR: \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 mg/24 hours; If the serum and urine M-protein are not measurable, a decrease of \>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria; If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \>=30%. In addition to the above criteria, if present at baseline, a \>=50% reduction in the size of soft tissue plasmacytomas was also required.

Time frame:
From randomization (Day -3) up to 2.4 years
Reported as:
Median · Months
Time to Response
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Time to Response0.82 (0.7 to 12.6)0.79 (0.4 to 15.5)
SecondaryDuration of Response (DOR)

DOR: participants with confirmed response (PR or better) as time between first documentation of response and disease progression per IMWG response criteria, or death due to PD, whichever occurs first. PD: Increase of 25% from lowest response value in any one of following: Serum M-component (absolute increase\>=0.5 g/dL); Urine M-component (absolute increase\>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10mg/dL); Only participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC%(absolute%\>=10%); Bone marrow PC's %: absolute%\>10%; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in the size of existing bone lesions or soft tissue plasmacytomas and Development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.

Time frame:
From first documentation of response up to 2.4 years
Reported as:
Median · Months
Duration of Response (DOR)
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Duration of Response (DOR)21.3 (18.4 to NA)NA (NA to NA)
SecondaryTime to Next Treatment (TNT)

Time to next treatment is defined as the time from randomization to the start of the next-line treatment. Kaplan-Meier method was used for the analysis.

Time frame:
From randomization (Day -3) up to 8.3 years
Reported as:
Median · Months
Time to Next Treatment (TNT)
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Time to Next Treatment (TNT)25.9 (23.4 to 28.6)66.8 (47.9 to NA)
SecondaryPercentage of Participants With Best M-protein Response

Percentage of participants with Best M- protein response of 100% reduction and \>=90% to \< 100% reduction were assessed. Best M-protein response was defined as the maximal percent reduction or the lowest percent increase from baseline in serum M-protein for participants with measurable heavy chain at baseline or urine M-protein for participants without measurable heavy chain, but with measurable light chain disease at baseline. For participants without measurable heavy chain and light chain disease at baseline, best response in serum free light chain (FLC) was defined as the maximal percent reduction or the lowest percent increase from baseline in the difference between involved and uninvolved serum FLC level (dFLC).

Time frame:
Up to 2.4 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Best M-protein Response
Percentage of participantsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Best M-protein response in serum: 100% reduction38.758.5
Best M-protein response in serum:>= 90 to < 100%14.615.2
Best M-protein response in urine:100% reduction69.490.5
Best M-protein response in urine:>=90 to < 100%13.97.1
Best response in dFLC:100% reduction00
Best response in dFLC: >=90% to < 100% reduction77.8100.0
SecondaryChange From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score

The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.

Time frame:
Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score
Units on a scaleVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Month 39.4 (7.1 to 11.6)8.5 (6.3 to 10.7)
Month 610.5 (8.1 to 12.9)10.8 (8.6 to 13.1)
Month 911.8 (9.4 to 14.3)11.1 (8.8 to 13.4)
Month 1211.2 (8.7 to 13.7)12.6 (10.3 to 14.9)
Month 1812.8 (10.1 to 15.6)12.5 (10.1 to 14.9)
Month 2411.8 (8.5 to 15.1)10.7 (8.2 to 13.3)
Month 3010.8 (7.3 to 14.3)12.4 (9.8 to 14.9)
Month 3610.8 (6.7 to 14.9)12.3 (9.6 to 14.9)
Month 426.5 (1.7 to 11.4)12.8 (10 to 15.6)
Month 486.2 (0.5 to 11.9)10.5 (7.5 to 13.5)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Global Health Scale

The EORTC QLQ-C30 is a 30 items self-reporting questionnaire, with a 1 week recall period, resulting in 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores are transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms. Negative change from baseline values for function and GHS scale indicated deterioration in quality of life or functioning and positive values indicate improvement.

Time frame:
Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Reported as:
Least squares mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Global Health Scale
Units on a scaleVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Month 34 (1.7 to 6.3)7.5 (5.2 to 9.7)
Month 68.8 (6.4 to 11.3)8.5 (6.2 to 10.8)
Month 910.2 (7.7 to 12.8)10.6 (8.2 to 12.9)
Month 1210.7 (8.2 to 13.3)11.4 (9 to 13.7)
Month 1811.8 (9 to 14.6)12.8 (10.3 to 15.3)
Month 2411.5 (8.1 to 15)9.5 (6.8 to 12.1)
Month 3010.8 (7.1 to 14.5)11.8 (9.2 to 14.5)
Month 368.6 (4.2 to 12.9)11.9 (9.1 to 14.6)
Month 424.8 (-0.3 to 9.9)10.4 (7.5 to 13.3)
Month 488.9 (2.8 to 14.9)9.8 (6.6 to 12.9)
SecondaryChange From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS)

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

Time frame:
Baseline (Day- 24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS)
Units on a scaleVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Month 34.27 ± 18.389.37 ± 20.222
Month 67.51 ± 17.95711.02 ± 20.168
Month 910.08 ± 19.47512.51 ± 20.564
Month 1211.1 ± 19.13910.93 ± 20.447
Month 1810.75 ± 21.14615.35 ± 21.168
Month 2410.62 ± 19.53112.17 ± 22.592
Month 3012.38 ± 21.81714.41 ± 21.305
Month 3612 ± 23.85613.94 ± 21.984
Month 4212.88 ± 23.78914.33 ± 21.502
Month 489.17 ± 18.61211.93 ± 24.031
SecondaryChange From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score

EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L descriptive system provides a profile of the participant's health state 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems and extreme problems) that reflect increasing levels of difficulty. The participant was asked to indicate his/her current health state by selecting the most appropriate level in each of the 5 dimensions. Responses to the 5 dimension scores were combined and converted into a single preference-weighted health utility index score 0 (0.0- worst health state) to 1 (1.0- better health state) representing the general health status of the individual based on the UK scoring algorithm.

Time frame:
Baseline (Day -24), Months 3, 6, 9, 12 ,18, 24, 30, 36, 42 and 48
Reported as:
Mean · Units on a scale
Change From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score
Units on a scaleVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Month 30.09 ± 0.3120.12 ± 0.266
Month 60.12 ± 0.2690.14 ± 0.271
Month 90.16 ± 0.270.16 ± 0.271
Month 120.15 ± 0.2810.17 ± 0.288
Month 180.14 ± 0.2680.17 ± 0.293
Month 240.15 ± 0.2520.18 ± 0.312
Month 300.16 ± 0.2910.19 ± 0.303
Month 360.16 ± 0.3150.21 ± 0.306
Month 420.08 ± 0.3030.2 ± 0.287
Month 480.07 ± 0.2460.15 ± 0.319
Post-hocProgression Free Survival at Data Cutoff Date of 24 June 2019

PFS: duration from date of randomization to PD/death, whichever occurs first. PD per IMWG criteria-Increase of 25% from lowest response value in one of following: Serum M-component (absolute increase \>=0.5 g/dL); Urine M-component (absolute increase \>=200 mg/24 hours); Only participants without measurable serum and urine M-protein levels: difference between involved and uninvolved FLC levels (absolute increase \>10 mg/dL); Only participants without measurable serum and urine M-protein levels, without measurable disease by FLC levels, bone marrow PC %(absolute % \>=10%); Bone marrow PC %: absolute % \>10 %; Definite development of new bone lesions/soft tissue plasmacytomas/definite increase in size of existing bone lesions/soft tissue plasmacytomas and development of hypercalcemia (corrected serum calcium \>11.5 mg/dL) that can be attributed solely to the PC proliferative disorder.

Time frame:
From randomization (Day -3) up to 4.4 years
Reported as:
Median · Months
Progression Free Survival at Data Cutoff Date of 24 June 2019
MonthsVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
Progression Free Survival at Data Cutoff Date of 24 June 201919.29 (17.97 to 20.40)36.40 (32.13 to 45.90)

Adverse events

Collected over All cause mortality: From randomization (Day -3) up to 8.3 years; Serious and Other AEs: From start of treatment (Day 1) up to 30 days after last dose of study treatment (up to 8.2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Velcade, Melphalan and Prednisone (VMP)217/356 (61%)117/354 (33.1%)331/354 (93.5%)
Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)172/350 (49.1%)186/346 (53.8%)329/346 (95.1%)
Most frequent serious events
Showing 10 of 256
Most frequent serious events
EventVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
PneumoniaInfections and infestations13/35453/346
BronchitisInfections and infestations2/35410/346
Lower Respiratory Tract InfectionInfections and infestations3/35410/346
AnaemiaBlood and lymphatic system disorders9/3548/346
Cardiac FailureCardiac disorders8/3542/346
Upper Respiratory Tract InfectionInfections and infestations4/3547/346
Back PainMusculoskeletal and connective tissue disorders3/3547/346
DyspnoeaRespiratory, thoracic and mediastinal disorders4/3547/346
Febrile NeutropeniaBlood and lymphatic system disorders7/3542/346
ThrombocytopeniaBlood and lymphatic system disorders4/3546/346
Most frequent other events
Showing 10 of 54
Most frequent other events
EventVelcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)
ThrombocytopeniaBlood and lymphatic system disorders189/354172/346
NeutropeniaBlood and lymphatic system disorders186/354174/346
AnaemiaBlood and lymphatic system disorders129/354110/346
Peripheral Sensory NeuropathyNervous system disorders122/354100/346
Upper Respiratory Tract InfectionInfections and infestations48/354103/346
DiarrhoeaGastrointestinal disorders87/354100/346
PyrexiaGeneral disorders70/35487/346
NauseaGastrointestinal disorders76/35476/346
BronchitisInfections and infestations25/35471/346
CoughRespiratory, thoracic and mediastinal disorders27/35470/346

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
Mean71.5 ± 5.8271.3 ± 6.6671.4 ± 6.25
Sex: Female, Male
Sex: Female, Male(Participants)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
Female189190379
Male167160327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
Hispanic or Latino162440
Not Hispanic or Latino332320652
Unknown or Not Reported8614
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
American Indian or Alaska Native000
Asian454792
Native Hawaiian or Other Pacific Islander000
Black or African American336
White304297601
More than one race000
Unknown or Not Reported437
Region of Enrollment
Region of Enrollment(Participants)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
Argentina224
Australia10515
Belgium8614
Brazil246
Bulgaria15823
Croatia224
Czech Republic292150
Georgia111122
Germany257
Greece151429
Hungary121426
Italy262854
Japan262450
Poland273966
Portugal437
Macedonia10111
Romania181028
Russia212243
Serbia3710
Korea, Republic of182341
Spain4756103
Turkey10515
Ukraine202848
United Kingdom15924
United States336
Stage of Disease (ISS)
Stage of Disease (ISS)(Participants)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
Stage I6769136
Stage II160139299
Stage III129142271
Time from multiple myeloma (MM) diagnosis
Time from multiple myeloma (MM) diagnosis(Months)Velcade, Melphalan and Prednisone (VMP)Daratumumab, Velcade, Melphalan and Prednisone (D-VMP)Total
Mean1.27 ± 1.7371.09 ± 1.0561.18 ± 1.442
08

Study locations

160 sites
  • California City, California, United States
  • Corona, California, United States
  • Fountain Valley, California, United States
  • Los Angeles, California, United States
  • Hialeah, Florida, United States
  • Orange Park, Florida, United States
  • Chicago, Illinois, United States
  • Springfield, Missouri, United States
  • Cleveland, Ohio, United States
  • Fredericksburg, Virginia, United States
  • Buenos Aires, Argentina
  • Ciudad Autonoma Buenos Aires, Argentina
  • Córdoba, Argentina
  • Santa Fe, Argentina
  • Adelaide, Australia
  • Bendigo, Australia
  • Camperdown, Australia
  • Geelong, Australia
  • Gosford, Australia
  • Greenslopes, Australia
  • Hobart, Australia
  • North Adelaide, Australia
  • Parkville, Australia
  • Antwerp, Belgium
  • Brussels, Belgium
  • Charleroi, Belgium
  • Ghent, Belgium
  • Kortrijk, Belgium
  • Roeselare, Belgium
  • Turnhout, Belgium
  • Yvoir, Belgium
  • Barretos, Brazil
  • Cuiaba - Mount, Brazil
  • Fortaleza, Brazil
  • Goiânia, Brazil
  • Natal, Brazil
  • Porto Alegre, Brazil
  • Ribeirão Preto, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Vratsa, Bulgaria
  • Zadar, Croatia
  • Zagreb, Croatia
  • Brno, Czechia
  • Hradec Králové, Czechia
  • Olomouc, Czechia
  • Ostrava-Poruba, Czechia
  • Prague, Czechia
  • Tbilisi, Georgia
  • Berlin, Germany
  • Dortmund, Germany
  • Karlsruhe, Germany
  • Potsdam, Germany
  • Saarbrücken, Germany
  • Stuttgart, Germany
  • Würzburg, Germany
  • Athens, Greece
  • Athens Attica, Greece
  • Pátrai, Greece
  • Thessaloniki, Greece
  • Budapest, Hungary
  • Debrecen, Hungary
  • Kaposvár, Hungary
  • Pécs, Hungary
  • Chiba, Japan
  • Hitachi, Japan
  • Kanazawa, Japan
  • Kawasaki, Japan
  • Kobe, Japan
  • Kurume, Japan
  • Matsuyama, Japan
  • Nagoya, Japan
  • Narita, Japan
  • Ohgaki, Japan
  • Okayama, Japan
  • Osaka, Japan
  • Sendai, Japan
  • Shibukawa, Japan
  • Shibuya City, Japan
  • Tachikawa, Japan
  • Toyohashi, Japan
  • Skopje, North Macedonia
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Chorzów, Poland
  • Gdansk, Poland
  • Legnica, Poland
  • Lublin, Poland
  • Opole, Poland
  • Słupsk, Poland
  • Warsaw, Poland
  • Warszawa Ul, Poland
  • Wroclaw, Poland
  • Lisbon, Portugal
  • Porto, Portugal
  • Brasov, Romania

Showing the first 100 of 160 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bahlis N, Facon T, San-Miguel J, Usmani SZ, Dimopoulos MA, Moreau P, Zweegman S, Perrot A, Manier S, Chari A, Raje N, Orlowski RZ, Goldschmidt H, Basu S, Hulin C, Weisel K, Mohty M, Leleu X, Plesner T, Jakubowiak A, Cook G, Quach H, Venner CP, Cavo M, Ngo M, Bolyard K, Carson R, Borgsten F, Mateos MV, Kumar SK. Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE. Blood Adv. 2026 Jul 14;10(13):4541-4550. doi: 10.1182/bloodadvances.2025019323. PubMed 42085642 ↗
  • Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Ngo M, Katz EG, Krevvata M, Bolyard K, Carson R, Borgsten F, Dimopoulos MA. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025 May;26(5):596-608. doi: 10.1016/S1470-2045(25)00018-X. Epub 2025 Apr 9. PubMed 40220771 ↗
  • Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Iida S, Blade J, Ukropec J, Pei H, Van Rampelbergh R, Kudva A, Qi M, San-Miguel J. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):785-798. doi: 10.1016/j.clml.2021.06.005. Epub 2021 Jun 18. PubMed 34344638 ↗
  • Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101. PubMed 34289038 ↗
  • San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 Jan 27;139(4):492-501. doi: 10.1182/blood.2020010439. PubMed 34269818 ↗
  • Knop S, Mateos MV, Dimopoulos MA, Suzuki K, Jakubowiak A, Doyen C, Lucio P, Nagy Z, Usenko G, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Losava G, Fujisaki T, Garg M, Wang J, Wroblewski S, Kudva A, Gries KS, Fastenau J, San-Miguel J, Cavo M. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 2;21(1):659. doi: 10.1186/s12885-021-08325-2. PubMed 34078314 ↗
  • Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10. PubMed 31836199 ↗
  • Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. PubMed 29231133 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Nov 2017, 35 months.

Results were first posted in Dec 2018, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 35 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2014
First posted
Jul 21, 2014
StartActual
Dec 9, 2014
Primary completionActual
Nov 21, 2017
CompletionActual
Aug 7, 2024
Results first posted
Dec 17, 2018
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02195479
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Dec 9, 2014
Primary completion
Nov 21, 2017
Completion
Aug 7, 2024
Results posted
Dec 17, 2018
Last update
Aug 22, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion